Search
nelarabine (Arranon)
Trademark: Arranon, FDA approved 2005
Indications:
- precursor T-lymphoblastic leukemia/lymphoma
* 89% 4 year progression-free survival reported with adjuvant nelarabine + chemotherapy vs 83% with chemotherapy alone [2]
Manufacturer: GSK
General
purine antimetabolite; antimetabolite; purine analog
antineoplastic agent (chemotherapeutic agent)
Database Correlations
PUBCHEM correlations
References
- Prescriber's Letter 13(2): 2006
Detail-Document#: 220215
(subscription needed) http://www.prescribersletter.com
- Ingram I.
First-Line Nelarabine Prolongs T-Cell ALL Remission.
Overall survival of 90% at 4 years is the highest reported yet
in these patients.
MedPage Today. May 16, 2018
https://www.medpagetoday.com/meetingcoverage/asco/72912
- Dunsmore KP et al
COG AALL0434: A randomized trial testing nelarabine in newly
diagnosed t-cell malignancy.
American Society of Clinical Oncology (ASCO) 2018; Abstract 10500.